

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO. FILING DATE		FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/441,061 11/16/1999		JOSEF ENDI	P564-9035	3812
	590 07/15/2002			
	KINTNER PLOTKI TICUT AVENUE, N.V	EXAMINER		
SUITE 400 WASHINGTO		DECLOUX, AMY M		
WASAING 10	TPE		ART UNIT	PAPER NUMBER
/	AND SE		1644	13
(:	III. 23 DOOL 2		DATE MAILED: 07/15/2002	10
THE STATE OF THE S	TE TRADENKE			
×	TE TRADE			

Please find below and/or attached an Office communication concerning this application or proceeding.

RECEIVED

JUL 2 4 2002

TECH CENTER 1600/2900



UNITED STATES DEPARTMENT OF COMMERCE Patent and Trademark Office COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

SERIAL NUMBER	FILING DATE		FIRST NAMED APPLICANT	A	ATTORNEY DOCKET NO	
09/441,061	11/16/99	Endl	P564-9035		64-9035	
·			1 [EXA	AMINER T	
	OIP E VO			Amy DeCloux		
	23 2002			ART UNIT	PAPER NUMBER	
	(nr 1,			1644	Š	

Please find below a communication from the EXAMINER in charge of this application

Commissioner of Patents

DATE MAILED:

This application fails to comply with the requirements of 37 C.F.R. 1.821-1.825 because there was no submission of a Sequence Listing, see the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures. Specifically, on psge 38 of the instant specification, two different sequences (GMAALPRLIAFTSE and GMAALPRLIAFT) are identified with the same SEQ ID NO tag (SEQ ID NO:14)

Only if said sequences are not listed in the sequence listings, then Applicants are required to submit a disk and paper copy of the sequences, along with a statement that the information recorded in computer readable form is identical to the written sequence listing, according to the attached "Notice to Comply with the Sequence Rules. Applicant is reminded of the sequence rules which require a submission for all sequences of more than 9 nucleotides or 3 amino acids (see 37 C.F.R. 1.821-1.825) and is also requested to carefully review the submitted specification for any and all sequences which require compliance with the rules.

Applicant is given TIME PERIOD of ONE EXTENDABLE MONTH, from the mailing date of this letter within which to comply with the sequence rules, 37 CFR 1.821 - 1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 CFR 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a). In no case may an applicant extend the period for reply beyond the SIX MONTH statutory period. Direct the reply to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the reply.

A reply to a notice to comply with the sequence rules should NOT be sent to the 20231 zip code address for the United States Patent and Trademark Office.

Please direct all replies to the United States Patent and Trademark Office via one (1) of the following:

 Electronically submitted through EFS-Bio (http://www.uspto.gov/ebc/efs/downloads/documents.htm, EFS Submission User Manual - ePAVE) 2. Mailed to: U.S. Patent and Trademark Office Box Sequence, P.O. Box 2327 Arlington, VA 22202

3. Mailed by Federal Express, United Parcel Service or other delivery service to:
U. S. Patent and Trademark Office
2011 South Clark Place
Customer Window, Box Sequence
Crystal Plaza Two, Lobby, Room 1B03
Arlington, Virginia 22202

4. Hand Carried directly to the Customer Window at: 2011 South Clark Place
Crystal Plaza Two, Lobby, Room 1B03, Box Sequence, Arlington, Virginia 22202

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Amy DeCloux whose telephone number is (703) 306-5821. The examiner can normally be reached Monday through Friday from 9:00 am to 6:00 pm. Or a message may be left on the examiner's voice mail service. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christina Chan can be reached on (703) 308-3973. Any inquiry of a general nature or relating to the status of this application should be directed to the Technology Center 1600 receptionist whose telephone number is (703) 308-0196.

Amy DeCloux, Ph.D.
Patent Examiner
Group 1646
Technology Center 1600
July 15, 2002

ang Plon 7-15-02 Application No.: 09/441,061
NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

	 This application clearly fails to comply with the requirements of 37 C.F.R. 1.3 attention is directed to these regulations, published at 1114 OG 29, May 15, 18230, May 1, 1990. 	821-1.825. Applicant's 1990 and at 55 FR					
	2. This application does not contain, as a separate part of the disclosure on partial Listing as required by 37 C.F.R. 1.821(c).	aper copy, a "Sequence					
	3. A copy of the "Sequence Listing" in computer readable form has not been so 37 C.F.R. 1.821(e).	ubmitted as required by					
	4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."						
	5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).						
	6. The paper copy of the "Sequence Listing" is not the same as the computer re "Sequence Listing" as required by 37 C.F.R. 1.821(e).	eadable from of the					
X	7. Other: See attached communication, regarding two peptides consisting both of which are identified by the same SEQ ID NO: tag.	of different sequences,					
App	plicant Must Provide: ONLY IF SAID SEQUENCES ARE NOT LISTED IN THE	SEQUENCE LISTING.					
X	An initial or <u>substitute</u> computer readable form (CRF) copy of the "Sequence Lis						
X	An <i>i</i> nitial or <u>substitute</u> paper copy of the "Sequence Listing", as well as an amer into the specification.	ndment directing its entry					
X	A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).						
For	questions regarding compliance to these requirements, please co	ntact:					
For	Rules Interpretation, call (703) 308-4216	RECEIVED					
ror Pat	CRF Submission Help, call (703) 308-4212 entIn Software Program Support (SIRA)	JUL 2 4 2002					
	Technical Assistance	TECH CENTER 1600/2900					

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE